The diagnosis and medical management of advanced neuroendocrine tumors.
The DOI matches its Crossref record; 657 of the 670 references it cites were found in a registry or an index.
Abstract
Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms that originate from endocrine glands such as the pituitary, the parathyroids, and the (neuroendocrine) adrenal, as well as endocrine islets within glandular tissue (thyroid or pancreatic) and cells dispersed between exocrine cells, such as endocrine cells of the digestive (gastroenteropancreatic) and respiratory tracts. Conventionally, NETs may present with a wide variety of functional or nonfunctional endocrine syndromes and may be familial and have other associated tumors. Assessment of specific or general tumor markers offers high sensitivity in establishing the diagnosis and can also have prognostic significance. Imaging modalities include endoscopic ultrasonography, computed tomography and magnetic resonance imaging, and particularly, scintigraphy with somatostatin analogs and metaiodobenzylguanidine. Successful treatment of disseminated NETs requires a multimodal approach; radical tumor surgery may be curative but is rarely possible. Well-differentiated and slow-growing gastroenteropancreatic tumors should be treated with somatostatin analogs or alpha-interferon, with chemotherapy being reserved for poorly differentiated and progressive tumors. Therapy with radionuclides may be used for tumors exhibiting uptake to a diagnostic scan, either after surgery to eradicate microscopic residual disease or later if conventional treatment or biotherapy fails. Maintenance of the quality of life should be a priority, particularly because patients with disseminated disease may experience prolonged survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With the combination of noninvasive and selected invasive modalities (particularly endoscopic ultrasound), most insulinomas are localized preoperatively (72, 78).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [72]
In the citing paper
“Although the results with a given method reflect the experience and expertise with that method at a given center, computed tomography, MRI, and transabdominal ultrasonography detect most insulinomas (71-73).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [72]
Citations
Cites
Items 601–657 of 657
The Role of Octreotide in the Treatment of Gastroenteropancreatic Endocrine Tumors
Degen, L. P., & Beglinger, C. (1999) · Digestion · doi:10.1159/000051475 · Cited by 17
The Glucagonoma Syndrome: Report of a Case
Domen, R. E., Shaffer, M. B., Finke, J., Sterin, W. K., & Hurst, C. B. (1980) · Archives of Internal Medicine · doi:10.1001/archinte.140.2.262 · Cited by 17
[Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].
Otte, A., Herrmann, R. P., Mäcke, H. R., & Müller‐Brand, J. (1999) · PubMed · Cited by 16
Prognosis of Children with Malignant Pheochromocytoma
Coutant, R., Pein, F. J. L., Adamsbaum, C., Oberlin, O., Dubousset, J., Jm, G., Teinturier, C., & Bougneres, P. F. (1999) · Hormone Research in Paediatrics · doi:10.1159/000023451 · Cited by 16
Genetic and Clinical Characteristics OF Multiple Endocrine Neoplasia Type 1
Skogseid, B. M., Larsson, C., & Öberg, K. (1991) · Acta Oncologica · doi:10.3109/02841869109092405 · Cited by 16
Faiss, S., Scherübl, H., Riecken, E. O., & Wiedenmann, B. J. (2009) · Digestion · doi:10.1159/000201404 · Cited by 16
Reduction in the Size of a Pheochromocytoma Pulmonary Metastasis by Metyrosine Therapy
Serri, O., Comtois, R., Bettez, P., Dubuc, G., Buu, N. T., & Kuchel, O. (1984) · New England Journal of Medicine · doi:10.1056/nejm198405103101917 · Cited by 16
Eigelberger, M. S., & Duh, Q. (2001) · Current Treatment Options in Oncology · doi:10.1007/s11864-001-0025-5 · Cited by 16
Radionuclide therapy of malignant pheochromocytoma with131I-MIBG
Nakabeppu, Y., & Nakajo, M. (1994) · Annals of Nuclear Medicine · doi:10.1007/bf03165029 · Cited by 15
Surgical strategy in the treatment of gastrointestinal neuroendocrine tumours
Falconi, M., Bettini, R., Scarpa, A., Capelli, P., & Pederzoli, P. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_2.s101 · Cited by 15
Therapy of pheochromocytoma with [131I]metaiodobenzylguanidine.
Fischer, M. (1991) · PubMed · Cited by 15
Medical Treatment of Neuroendocrine Tumors
Bajetta, E., Bartolomeo, M. D., Zilembo, N., & Bochicchio, A. M. (1993) · Tumori Journal · doi:10.1177/030089169307900602 · Cited by 15
The management of Zollinger—Ellison syndrome
Maton, P. N. (1993) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1993.tb00122.x · Cited by 14
Janson, E. T., & Öberg, K. (1996) · Baillière s Clinical Gastroenterology · doi:10.1016/s0950-3528(96)90015-9 · Cited by 14
Radiolabeling approaches for cholecystokinin B receptor imaging
Aloj, L., Panico, M., Caracò, C., Zannetti, A., Vecchio, S. D., Nuzzo, C., Arra, C., Morelli, G., Tesauro, D., Luca, S. D., et al. (2002) · Biopolymers · doi:10.1002/bip.10347 · Cited by 14
MR Imaging of Pancreatic Disorders
Outwater, E. K., & Siegelman, E. S. (1996) · Topics in Magnetic Resonance Imaging · doi:10.1097/00002142-199610000-00003 · Cited by 14
Minimal residual disease in thyroid carcinoma
Weber, T., & Klar, E. (2001) · Seminars in Surgical Oncology · doi:10.1002/ssu.1044 · Cited by 14
Apoptosis in neuroendocrine tumours
Wang, D. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00756.x · Cited by 14
Management of Enterochromaffin-like Gastric Carcinoid Tumour Metastasized to the Liver
Kouraklis, G., Misiakos, E., Glinavou, A., Raftopoulos, J., & Karatzas, G. (2002) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655202753416957 · Cited by 14
Intra-operative procedures to localize endocrine tumours of the pancreas and duodenum.
Norton, J. A. (1999) · PubMed · Cited by 14
van der Horst‐Schrivers, A. N. A., Wymenga, A. N. M., & de Vries, E. G. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmc030888 · Cited by 14
A cross-sectional study of vitamin intake in postoperative non-small cell lung cancer patients
Jatoi, A., Daly, B. D. T., Kramer, G., & Mason, J. B. (1998) · Journal of Surgical Oncology · doi:10.1002/(sici)1096-9098(199808)68:4<242::aid-jso7>3.0.co;2-4 · Cited by 13
Burns, A. R., & Dackiw, A. P. B. (2003) · Current Treatment Options in Oncology · doi:10.1007/s11864-003-0006-y · Cited by 13
Control of Growth in Neuroendocrine Gastro-Enteropancreatic Tumours
Arnold, R., & Frank, M. L. (2009) · Digestion · doi:10.1159/000201400 · Cited by 12
Absence of mutations in the MEN2A region of the ret proto‐oncogene in non‐MEN 2A phaeochromocytomas
Chew, S. L., Lavender, P., Jain, A. K., Weber, A., Ross, R. J. M., Wass, J. A. H., Besser, O. M., & Clark, A. J. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02593.x · Cited by 12
McStay, M., & Caplin, M. E. (2002) · PubMed · Cited by 12
Palliative Chemotherapy for Malignant Pheochromocytoma: Symptomatic Palliation of Two Cases.
Iwabuchi, M., Oki, Y., & Nakamura, H. (1999) · Internal Medicine · doi:10.2169/internalmedicine.38.433 · Cited by 11
Bishop, A. E., & Polak, J. M. (1996) · Baillière s Clinical Gastroenterology · doi:10.1016/s0950-3528(96)90013-5 · Cited by 11
Treatment of metastatic para-aortic paraganglioma by surgery, radiotherapy and I-131 mIBG.
Ball, A. B. S., Tait, D., Fisher, C., Sinnett, H. D., & Harmer, C. (1991) · PubMed · Cited by 10
Colombo, L., Lomuscio, G., Vignati, A., & Dottorini, M. E. (1991) · PubMed · Cited by 10
Schmid, R. M., Allescher, H. D., Schepp, W., Hölscher, A., Siewert, R., Schusdziarra, V., & Claßen, M. (1988) · PubMed · Cited by 10
Anomalous Glucose and Insulin Responses in Patients With Insulinoma: Caveats for Diagnosis
Dons, R. F., Hodge, J., Ginsberg, B. H., Brennan, M. F., Cryer, P. E., Kourides, I. A., & Gorden, P. (1985) · Archives of Internal Medicine · doi:10.1001/archinte.145.10.1861 · Cited by 10
Pape, U., Höcker, M. R., Seuß, U., & Wiedenmann, B. (2000) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-59587-5_4 · Cited by 9
Results of [131I]metaiodobenzylguanidine treatment in metastatic malignant phaeochromocytoma.
Bestagno, M., Pizzocaro, C., Maira, G., Terzi, A. C., Panarotto, M. B., & Guerra, P. (1991) · PubMed · Cited by 9
Troncone, L., Rufini, V., Maussier, M. L., Valenza, V., Ms, D., Luzi, S., & De Santis, M. (1991) · PubMed · Cited by 9
Bombardieri, E., Maccauro, M., Castellani, M. R., Chiti, A., Procopio, G., Bajetta, E., & Seregni, E. C. (2001) · PubMed · Cited by 9
New advances in peptide receptor radionuclide therapy
Jong, M., & Krenning, E. (2002) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 7
Juhlin, C., Rastad, J., Åkerström, G., Papanicolaou, V., Öberg, K., Arnberg, H., Klareskog, L., & Lörelius, L. (1994) · Cancer · doi:10.1002/1097-0142(19940301)73:5<1346::aid-cncr2820730507>3.0.co;2-c · Cited by 6
Carcinoid Tumor Regression With High-Dose Octreotide Acetate: A Patient Report
Lokich, J. J. (1998) · American Journal of Clinical Oncology · doi:10.1097/00000421-199806000-00007 · Cited by 6
Somatostatin receptor expression in multiple endocrine neoplasia and in von hippel–lindau disease
Lamberts, Hofland, L. J., van der Lely, A. J., & Herder, D. W. W. (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00340.x · Cited by 6
Oncogenic co-operation in -cell tumorigenesis
Pelengaris, S., & Khan, M. (2001) · Cited by 6
Palliation of malignant phaeochromocytoma with combination chemotherapy
Senan, S., Reed, N. S., & Connell, J. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90173-y · Cited by 6
Veenhof, C. H. N. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_4.s185 · Cited by 5
Papamichael, D., Seymour, M., Rt, P., Wilson, P., Cj, G., BESSER, G. M., & Slevin, M. L. (1998) · PubMed · Cited by 5
Self-citationHartley, A., Spooner, D., & Brunt, A. M. (2001) · Clinical Oncology · doi:10.1007/s001740170036 · Cited by 5
Therapie eines malignen sympathischen Paraganglioms des Zuckerkandl'schen Organs — ein Fallbericht
Schuppert, F., Scheumann, G. F. W., Schöber, C., Overbeck, J., Schürmeyer, T. H., Schmoll, H., Dralle, H., & Mühlen, A. V. Z. (1991) · Journal of Molecular Medicine · doi:10.1007/bf01798547 · Cited by 4
What Causes Tetany After Removal of the Parathyroid Glands? MacCallum, Voegtlin, and Calcium
Sawin, C. T. (2003) · The Endocrinologist · doi:10.1097/00019616-200301000-00001 · Cited by 4
Öberg, K. (1999) · PubMed · Cited by 4
Islet cell tumours: diagnosis and medical management
Taheri, S., & Meeran, K. M. (2000) · Hospital Medicine · doi:10.12968/hosp.2000.61.12.1478 · Cited by 3
Octreotide agent shows peptide imaging potential.
Krenning, E. P., Dj, K., Oei, Y., Reubi, J., & Lamberts, S. W. J. (1993) · PubMed · Cited by 3
Modlin, I. M., Lye, K. D., & Kidd, M. S. (2003) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2003.08.018 · Cited by 3
Intralesional interferon for the treatment of metastatic carcinoid tumours
Schneider, H. J., Heddle, R. M., Downes, M. O., Wan, K. M. B., & Smedley, H. M. (1998) · Clinical Oncology · doi:10.1016/s0936-6555(05)80494-7 · Cited by 2
[Therapy of metastatic endocrine tumors of the gastrointestinal tract].
Arnold, R., & Hiddemann, W. (1996) · PubMed · Cited by 2
Overexpression of glut-1 glucose transporter in human breast cancer an immunohistochemical study
(1993) · doi:10.1002/1097-0142(19931115)72:10 · Cited by 1
[Screening for hereditary neuroendocrine tumors of the gastrointestinal-pancreatic system].
Scherübl, H., Bredeek, U. F., Zimmer, T., & Riecken, E. O. (1996) · PubMed · Cited by 1
p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan
Nose, H., Imazeki, F., Ohto, M., & Omata, M. (1993) · Cancer · doi:10.1002/1097-0142(19930715)72:2
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Research works printed but not linked: 3
- Krenning, 1994, Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide., Semin Oncol, 21, 6
- Janson, 2000, Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors., J Nucl Med, 41, 1514
- Bartsch, 1990, Treatment of metastatic carcinoid tumors by recombinant human interferon-α. Results from a phase II study., J Cancer Res Clin Oncol, 116, 305
Cited by
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Self-citationClinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Role of tumor microenvironment in tumorigenesis
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1410 · Cited by 1,277
Self-citation
Metadata
- Authors
- Kaltsas, G. A., Besser, G. M., & Grossman, A. B.
- Affiliations
- St Bartholomew's Hospital (GB)
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2004-06-01
- Volume
- 25
- Issue
- 3
- Pages
- 458-511
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2031301095
- Semantic Scholar
- b09a37699a89446c4662f1bc87eb975bf31118b7
- Cited by
- 674
- References
- 670
- Citations by year
- 2026: 4 · 2025: 19 · 2024: 17 · 2023: 26 · 2022: 17 · 2021: 23 · 2020: 23 · 2019: 24 · 2018: 31 · 2017: 27 · 2016: 34 · 2015: 46 · 2014: 30 · 2013: 37 · 2012: 49
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- neuroendocrine tumors, diagnosis, tumor markers, endocrine syndromes, somatostatin analogues, MIBG scintigraphy, endoscopic ultrasound, interferon-alpha, chemotherapy, radionuclide therapy, multimodal therapy, quality of life
- MeSH terms
- Adrenal Gland Neoplasms, Animals, Antineoplastic Combined Chemotherapy Protocols, Gastrointestinal Neoplasms, Humans, Pancreatic Neoplasms, Parathyroid Neoplasms, Pituitary Neoplasms, Prognosis, Quality of Life, Sensitivity and Specificity, Somatostatin, Thyroid Neoplasms, Tomography, X-Ray Computed, Biomarkers, Tumor, Interferon-alpha, Carcinoma, Neuroendocrine, Neuroendocrine Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.